Skip to content
Top Globe News – Lifestyle
Author:
KAZIA THERAPEUTICS LIMITED.
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
November 2, 2026
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
October 29, 2026
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
September 22, 2026
Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer
September 9, 2026
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
September 1, 2026
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1, 2026
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
September 1, 2026
Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
August 28, 2026
Kazia Therapeutics Limited Announces Proposed Public Offering
August 28, 2026
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026
1
2
Next Page
→